Arsenic exposure is associated with pediatric pneumonia in rural Bangladesh: a case control study by unknown
RESEARCH Open Access
Arsenic exposure is associated with pediatric
pneumonia in rural Bangladesh: a case control
study
Christine Marie George1,4*, W. Abdullah Brooks1,2, Joseph H Graziano3, Bareng A. S. Nonyane1, Lokman Hossain2,
Doli Goswami2, Khalequzzaman Zaman2, Mohammad Yunus2, Al Fazal Khan2, Yasmin Jahan2, Dilruba Ahmed2,
Vesna Slavkovich3, Melissa Higdon1, Maria Deloria-Knoll1 and Katherine L. O’ Brien1
Abstract
Background: Pneumonia is the leading cause of death for children under 5 years of age globally, making research
on modifiable risk factors for childhood pneumonia important for reducing this disease burden. Millions of children
globally are exposed to elevated levels of arsenic in drinking water. However, there is limited data on the
association between arsenic exposure and respiratory infections, particularly among pediatric populations.
Methods: This case control study of 153 pneumonia cases and 296 controls 28 days to 59 months of age in rural
Bangladesh is the first to assess whether arsenic exposure is a risk factor for pneumonia in a pediatric population.
Cases had physician diagnosed World Health Organization defined severe or very severe pneumonia. Urine
collected during hospitalization (hospital admission time point) and 30 days later (convalescent time point) from
cases and a single specimen from community controls was tested for urinary arsenic by graphite furnace atomic
absorption.
Results: The odds for pneumonia was nearly double for children with urinary arsenic concentrations higher than
the first quartile (≥6 μg/L) at the hospital admission time point (Odd Ratio (OR):1.88 (95 % Confidence Interval
(CI): 1.01, 3.53)), after adjustment for urinary creatinine, weight for height, breastfeeding, paternal education, age,
and number of people in the household. This was consistent with findings at the convalescent time point where
the adjusted OR for children with urinary arsenic concentrations greater than the first quartile (≥6 μg/L) was 2.32
(95 % CI: 1.33, 4.02).
Conclusion: We observed a nearly two times higher odds of pneumonia for children with creatinine adjusted
urinary arsenic concentrations greater than the first quartile (≥6 μg/L) at the hospital admission time point. This
novel finding suggests that low to moderate arsenic exposure may be a risk factor for pneumonia in children
under 5 years of age.
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Introduction
Millions of people in countries around the world are
exposed to elevated levels of arsenic in drinking water.
In Bangladesh alone, it has been estimated that more than
35 million people are exposed to naturally occurring ar-
senic in drinking water at levels exceeding the World
Health Organization guideline of 10 μg/L [1]. This arsenic
is believed to result from arsenic-rich iron oxides in sedi-
ments being dissolved and released into the groundwater
aquifer [2, 3]. There is a growing body of literature linking
arsenic exposure to adverse respiratory outcomes includ-
ing reduced lung function [4–6], cough [7–13], and less
conclusively lower respiratory tract infections [14], bron-
chitis [12, 15, 16], and pulmonary tuberculosis mortality
[17]. However, most studies have been conducted in adult
populations, and there have been no studies to date evalu-
ating the association between arsenic and pneumonia in
pediatric populations. Pneumonia is the leading cause of
death for children under 5 years of age globally, making
research on modifiable risk factors for childhood pneumo-
nia important for reducing this disease burden [18].
Although there are no published studies assessing the
association between arsenic and pneumonia there are
four cohort studies that have investigated the association
between arsenic exposure and pediatric respiratory dis-
eases [14, 19–21]. A cohort study in Matlab, Bangladesh
found that maternal urinary arsenic concentrations during
gestation were negatively associated with interleukin-7,
lactoferrin, and child thymic index at 12 months, and
positively associated with the number of days of acute
respiratory infections at 6–12 months [14]. A second
cohort study in Matlab found that infants of mothers with
urinary arsenic concentrations in the highest quintile dur-
ing gestation had a significantly increased relative risk of
lower respiratory tract infection at 12 months compared
to those in the lowest quintile [22]. In New Hampshire, a
cohort study reported a significant association between in
utero arsenic exposure and upper respiratory infections
in 4 month old infants [21]. Finally, a fourth recently
published cohort study from Matlab, Bangladesh found
a significant association between in utero and early life
arsenic exposure and wheezing and shortness of breath
[20]. These cohort studies were important to the field
because they demonstrated a significant association be-
tween in utero arsenic exposure and subsequent respiratory
infections. However, one potential limitation was the use of
caregiver reported respiratory symptoms which could be
subject to reporting bias, particularly if caregivers knew the
arsenic status of their household wells.
Animal studies have found that arsenic in drinking water
causes immune suppression that is suspected to affect the
pulmonary defense system [23–28]. In Kozul et al. arsenic
exposure was associated with increased morbidity and
pulmonary influenza virus titers in mice exposed to H1N1
virus [29]. In another animal study, tumor necrosis factor-
α (TNF-α) and IL1b were significantly altered in the lungs
of arsenic exposed mice [30]. Arsenic has also been shown
to interfere with the Janus kinase-signal transducer and
activator of transcription (JAK-STAT) pathway, essential
for mediating cytokine receptor signaling pathways and
the regulation of cell growth, by suppressing cytokine
function and production [27]. In human studies, a study
in Mexico found that increased urinary arsenic was signifi-
cantly associated with reduced percentages of CD4 T cells
and interleukin (IL)-2 secretion levels [31]. Consistent
with this finding, a study in West Bengal found that ar-
senic exposure was associated with reduced T-cell prolifer-
ation and cytokine secretion (TNF-α,Interferon-γ, IL-2,
IL-10) [32]. A study in Bangladesh found that arsenic
exposure from drinking water during pregnancy was as-
sociated with lower breast milk concentrations of IL-7 and
lactoferrin [14]. Furthermore, another recent study in
Bangladesh found that prenatal arsenic exposure was asso-
ciated with a decreased percentage of CD4 T cells in cord
blood [33]. These findings suggest that arsenic exposure
may alter the activation of CD4 T cells resulting in re-
duced cytokine secretion and immune suppression.
Given this evidence, we hypothesize that arsenic ex-
posure suppresses immune function in children making
them more susceptibility to pneumonia. In an initial at-
tempt to test our hypothesis, we have conducted the first
study to assess the relationship between arsenic exposure
and pneumonia in a pediatric population.
Patients and methods
This study was nested within the Pneumonia Etiology
Research for Child Health (PERCH) study, and was
undertaken at the Matlab, Bangladesh site. PERCH is a
case–control study conducted in 7 countries (Bangladesh,
Thailand, Kenya, The Gambia, Mali, Zambia, and South
Africa) to determine the etiology of severe and very severe
hospitalized pneumonia and associated risk factors in chil-
dren under 5 years of age [34]. These sites were selected
because they were regions predicted to have the most se-
vere pneumonia in children in 2015. In Bangladesh there
were two PERCH sites, one in urban Dhaka, Bangladesh
and one in rural Matlab, Bangladesh. Data from the Dhaka
site was not included in our current study because this site
uses a low arsenic municipal water supply.
Matlab is a rural area in the Chandpur District of
Bangladesh, and is part of the International Centre for
Diarrhoeal Disease Research, Bangladesh (icddr,b) Health
and Demographic Surveillance System (HDSS). The Matlab
HDSS maintains a registry of births, deaths, migrations,
and vital health outcomes for over 220,000 individuals [35].
Previous studies conducted in the Matlab HDSS report that
70 % of the 13,286 wells in the HDSS contain arsenic ex-
ceeding the World Health Organization (WHO) guideline
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of 10 μg/L [35]. All individuals living within the Matlab
HDSS are registered in the HDSS database. New residents
are registered when they enter the study area.
All severe and very severe pneumonia cases were re-
cruited from Matlab icddr,b Hospital located within the
HDSS catchment area. There are no other hospitals in
the Matlab HDSS area. Cases were defined as children
28 days to 59 months of age hospitalized with physician
diagnosed World Health Organization (WHO) defined
severe or very severe pneumonia. Severe pneumonia was
defined as children presenting with a cough or difficulty
breathing, and lower chest wall in-drawing. Very severe
pneumonia was defined as children with a cough or dif-
ficulty breathing and any of the following symptoms:
central cyanosis, unable to feed, vomiting, convulsions,
lethargy, impaired consciousness, or head nodding [36].
Case inclusion criteria were that they lived within the
Matlab HDSS catchment area. The case exclusion criteria
were if the child had been hospitalized in the past 14 days
or if the child had been discharged from the Matlab
icddr,b hospital in the past 30 days as a PERCH case.
Cases were enrolled over a 21 month period including en-
rollment during nights and weekends to ensure that they
were representative of the disease occurrence in the
population.
Controls were frequency matched to cases based on the
following age strata: 28 days to <6 months, 6 to <12 months,
12 to <24 months, and 24–59 months. Controls were ran-
domly selected within these age strata from their homes
using the Matlab HDSS database. If a child met the study
eligibility criteria they were ask to come to Matlab icddr,b
hospital for a clinical examination by a physician. The in-
clusion criteria for controls were that they were children
28 days to 59 months of age and living within the Matlab
HDSS catchment area. The control exclusion criteria were
the following: (1) child had been hospitalized in the past
14 days; (2) child had been discharged from the Matlab
icddr,b hospital in the past 30 days as a PERCH case; (3)
child appeared very sick requiring urgent medical atten-
tion; or (4) child was found to have WHO defined se-
vere or very severe pneumonia during their clinical
examination. A minimum of 12 community controls were
recruited per month; and in months when more than 12
cases were enrolled, additional controls were enrolled so
as to frequency-match by season to cases [34].
Elimination of ingested arsenic occurs predominately
via the urine [37–39]. Urinary arsenic has been found to
be a reliable biomarker of chronic arsenic exposure and is
relatively stable over time if the source of drinking water re-
mains constant [40–43]. Two urine samples were collected
from cases: after confirmation of PERCH eligibility at
icddr,b Matlab hospital (“hospital admission”) and ap-
proximately 30 days after the hospital admission date
(“convalescent”). Controls had a single urine specimen
collected; this took place during their clinical examination
at the icddr,b Matlab hospital for the study enrollment ac-
tivities. All urine samples were collected from study par-
ticipants in 50 ml urine bags, transferred to two 5 ml acid
washed tubes, and frozen at −20 °C at the local laboratory
in Dhaka, Bangladesh until shipment on dry ice to the
Trace Metals Core Laboratory at Columbia University
for analysis. Total urinary arsenic concentration was
measured by graphite furnace atomic absorption, using
a Perkin-Elmer Analyst 600 graphite furnace system
(Waltham, MA) with a detection limit of 2 μg/L [44].
Urinary creatinine was quantified using a method based
on the Jaffe reaction [45]. This measure was used to ad-
just each child’s urinary arsenic concentration for their
hydration status [46].
Our laboratory participates in the Interlaboratory
Comparison Program for Metals in Biological Matrices
run by The Centre de Toxicology du Quebec (CTQ). We
receive samples of unknown arsenic concentration five
times a year. Each batch of samples contains three urines
with varying arsenic concentrations, which we analyze and
report back to CTQ. The coefficient of correlation
between reported and target values for 2013, when
PERCH study urine samples were analyzed, was 0.99 with
a z-score of 1.4 (<2 = satisfactory). Every day after initial
calibration, three urine samples with known concentra-
tions from CTQ are analyzed. They have to be within the
established range for the instrument to continue running
the unknown samples. Concentrations of known urine
samples are chosen to cover the low, medium, and high
range of the calibration curve. Throughout the day a
medium quality control sample (QCS) is analyzed every
10 samples, and if it’s out of the established range, in-
strument recalibration is performed.
A questionnaire was administered to the child’s caregiver
to obtain information on household socio-demographic
characteristics and the child’s health status. Breastfeeding in
the prior week was categorized as the following: exclusive,
mixed with other foods or fluids, and none. Paternal educa-
tion was categorized as no formal education, 1–5 years of
education, 5–10 years of education, and greater than
10 years of education. Information was also collected on
the number of people living within the household, this vari-
able was log transformed in the logistic regression models.
In addition, research assistants trained in standardized
anthropometry, measured the child’s weight and height.
Height and weight measurements were used to calculate
z-scores according to the WHO child growth standards
[47]. Wasting was defined as z-scores less than −2 SD
for weight for height.
Our sample for this nested case control study within
the PERCH study was based on the number of pneumonia
cases recruited at the Matlab, Bangladesh site between
January 2012 and September 2013. We estimated there
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would be approximately 178 cases (both severe and very
severe pneumonia) and 226 controls enrolled into the
PERCH study at the Matlab site over our study period.
We conducted our power calculation in G*Power 3.1.3.
Based on this anticipated sample size of 178 cases and 226
controls, we would have been able to detect a true dif-
ference in mean urinary arsenic concentrations in cases
and controls of 17 µg/L creatinine, adjusted for creatinine
concentrations, with a power of 80 % and a type 1 error
of 0.05.
Logistic regression was used to determine if arsenic
exposure, assessed by urinary arsenic concentrations,
significantly increased the odds of being a pneumonia
case. The main predictor, urinary arsenic concentration,
was divided into quartiles. Covariates that had a p-value less
than 0.1 or changed the ORs of pneumonia by more than
5 % in a model with the outcome and urinary arsenic were
included in the multivariable logistic regression model as
potential confounders. We compared both the hospital
admission case urine and the convalescent case urine
with the control urine. Data was divided into quartiles
at the hospital admission time point using the hospital
admission case urines and the control urines. Quartiles
at the case convalescent time points were calculated
using the case convalescent urine samples and the con-
trol urine samples. Because a small proportion of cases
(<12 %) had very severe pneumonia, we included all
cases, regardless of severity, in a single category in the
main analysis. A sensitivity analysis was also performed
to investigate the impact of very severe pneumonia on
our observed associations. For this sensitivity analysis
all regression models were performed without very se-
vere pneumonia cases in the models. All analyses were
performed using SAS, version 9.3 (SAS Institute Inc.,
Cary, NC, USA).
Informed consent from a guardian was obtained for
cases and controls. All study procedures were approved
by the research ethics committees of icddr,b and Johns
Hopkins Bloomberg School of Public Health.
Results
A total of 205 cases and 306 controls were recruited for
the PERCH study at the Matlab, Bangladesh site be-
tween January 2012 and September 2013. Ninety-eight
percent of cases (201/205) produced a urine sample at
icddr,b Matlab hospital at the hospital admission time-
point, and 75 % (153/205) at the convalescent timepoint.
Ninety-seven percent (296/306) of controls produced a
urine sample. Cases and controls differed significantly by
gender, weight for height, paternal education, and floor
type of household (Table 1). Most children (95 %) lived
in households where shallow wells were the main source
of drinking water. Four case children did not produce a
urine sample during our convalescent visit, 8 children
migrated outside the study area or could not be located,
two children died, three children did not produce enough
urine for sample analysis, and 31 children had their
convalescent visit after our study period had ended. There
were no significant differences observed in demographic
characteristics between cases which provided a urine sam-
ple at the convalescent time point, and those that did not
(Additional file 1: Table S1). The mean duration of diffi-
culty breathing for cases was 2 days (range 1–7 days).
Thirty four percent of the 153 cases enrolled were fully
vaccinated for Haemophilus Influenzae Type b (Hib)
(>3 doses or ≥1 if the child is 12 months of age or older),
and 66 % of the 296 controls were fully vaccinated for Hib
(p = 0.0009).
Creatinine concentrations of the admission case urine
samples were significantly higher than those of control
(p = <0.0001) and case convalescent (p = <0.0001) urine
samples. There was no significant difference in urinary
creatinine concentrations between control and case con-
valescent urine samples (p = 0.14). Cases were present at
the hospital facility for significantly longer than controls
before a urine sample was provided (p = <0.0001) (me-
dian hours 3.2 vs. 0.75). Among the 153 cases, the spear-
man correlation coefficients between the urinary arsenic
concentrations at the hospital admission and the conva-
lescent time points was 0.73 (p <0.001). The p-value of
the paired t- test of the urinary arsenic concentrations of
the urine samples collected at the hospital admission
and convalescent time points was 0.001.
The odds ratios (OR) for severe and very severe pneumo-
nia in increasing quartiles of urinary arsenic concentrations
at the hospital admission time point were 1.00 (reference),
1.75 (95 % confidence interval (CI): (0.90, 3.40)), 2.11 (95 %
CI: (1.01, 4.34)), and 2.04 (95 % CI: (0.92, 4.51)), after ad-
justment for urinary creatinine concentrations, weight for
height, breastfeeding, paternal education, age, and number
of people in the household (Table 2). Furthermore, there
was a significant association between a urinary arsenic con-
centration higher than the first quartile (6 μg/L or greater)
at the hospital admission time point and increased odds
of pneumonia in the crude (2.28 (95 % CI: 1.37, 3.79))
and adjusted models (1.88 (95 % CI: 1.01, 3.50)). For
the sensitivity analysis at the hospital admission time
point, the odds ratios for severe pneumonia and urinary
arsenic concentrations adjusted for creatinine were 1.00
(reference), 2.12 (95 % confidence interval (CI): (1.04,
4.32)), 2.35 (95 % CI: (1.07, 5.17)), and 2.36 (95 % CI: (1.02,
5.42)), after adjustment for study covariates.
For the convalescent time point, the adjusted ORs
for pneumonia in increasing quartiles of urinary arsenic
were 1.00 (reference), 2.25 (95 % CI: 1.23, 4.11), 2.29 (95 %
CI: 1.17, 4.47), and 2.56 (95 % CI: 1.27, 5.15) (Table 3). In
addition, there was a significant association between a
urinary arsenic concentration higher than the first quartile
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Table 1 Characteristics of the study population by time point of urine collection
Controls Cases
Hospital Admission time point Convalescent time point
% N % N p-valuea % N p-valueb
Number of children 296 201 153
Urinary arsenic concentration (μg/L)
(Median (Interquartile Range))
14.0 (4.5–41.0) 296 24.0 (8.0–64.0) 201 <0.0001 16.0 (7.0–48.0) 153 0.26
Urinary creatinine concentration (mg/ dl)
(Median (Interquartile Range))
22.4 (13.1–38.4) 296 48.1 (26.0–77.5) 201 <0.0001 19.1 (11.5–35.2) 153 0.14
Gender
Female 54 % 161 57 % 115 0.01 64 % 98 0.01
Age (Months)
Median (Interquartile Range) (Months) 10.0 (5.0–20.0) 296 13.0 (6.0–23.0) 201 0.88 12.0 (6.0–22.0) 153 0.90
0–5 33 % 99 25 % 50 24 % 36
6–11 18 % 53 28 % 56 23 % 35
12–23 27 % 80 25 % 50 32 % 49
24–59 22 % 64 22 % 45 22 % 33
Breastfed in the prior week
Exclusive 24 % 71 23 % 45 0.33 22 % 33 0.50
Mixed 55 % 161 56 % 112 59 % 89
None 21 % 61 22 % 43 20 % 30
Case definition
Severe pneumonia – – 89 % 179 88 % 135
Very severe pneumonia – – 11 % 22 12 % 18
WHO weight for height
z-score less than −2 SDs 11 % 33 21 % 43 0.002 20 % 31 0.01
z-score greater or equal to −2 SDs 89 % 259 79 % 158 80 % 122
Paternal education
No formal education 12 % 35 18 % 36 0.07 18 % 28 0.03
1–5 years 21 % 61 20 % 41 22 % 34
5–10 years 47 % 139 49 % 99 49 % 75
Greater than 10 years 20 % 59 12 % 25 10 % 16
Number of individuals living in household
(Median (Interquartile Range))
5 (4–7) 296 5 (4–6) 201 0.05 5 (4–6) 153 0.10
Main source of drinking waterc
Piped water 1 % 4 2 % 5 0.76 3 % 5 0.69
Tube well 98 % 288 95 % 191 72 % 145
River, stream, pond, lake 1 % 4 2 % 4 2 % 3
Other 0 % 0 <1 % 1 0 % 0
Floor of household
Natural floor (sand/earth/dung) 79 % 233 86 % 173 0.04 86 % 131 0.08
Finished floor (wood/tiles/cement/carpet) 21 % 63 14 % 28 14 % 22
Time-lapsed between hospital admission and urine
collection in hours (Median (Interquartile Range))
0.75 (0.5–1.1) 290 3.2 (2.1–5.0) 193 <0.0001 – – –
aControl and case at admission time point compared using a two sample t-test for continuous variables and chi-square test for categorical variables
bControl and case at convalescent time point compared using a two sample t-test for continuous variables and chi-square test for categorical variables
cTub well compared to all other drinking water sources
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(6 μg/L or greater) at the convalescent time point and
increased odds of pneumonia in the crude (1.65 (95 % CL:
1.03, 2.65)) and adjusted models (2.32 (95 % CI: 1.33, 4.02).
The ORs for total urinary arsenic unadjusted for urinary
creatinine are shown in Tables 4 and 5. At the hospital
time point the adjusted ORs for pneumonia in increasing
quartiles of urinary arsenic were 1.00 (reference), 2.38
(95 % CI: (1.25, 4.53)), 3.77(95 % CI: (1.88, 7.56)), and 4.42
(95 % CI: (2.30, 9.67)) (Table 4). For convalescent time
point, the adjusted ORs for pneumonia in increasing
quartiles of urinary arsenic were 1.00 (reference), 2.10
(95 % confidence interval (CI): (1.16, 3.81)), 1.97 (95 %
CI: (1.03, 3.79)), and 2.03 (95 % CI: (1.04, 3.97)) (Table 5).
There was also a significant association between a urinary
arsenic concentration higher than the first quartile (6 μg/L
or greater) at the hospital admission (OR: 3.12 (95 %
CI: 1.74, 5.61)) and convalescent time point (OR: 2.05
(95 % CI: 1.20, 3.51) in the adjusted models.
Table 2 Crude and adjusted odds ratios of case and control urine samples at the hospital admission timepoint* (urinary creatinine
in adjusted model)
Hospital Admission Time point
All pneumonia cases (severe and very severe)
Total urinary arsenic (μg/L) Case urine samples (N = 153) Control urine samples (N = 296) Crude OR 95 % CI Adjusted OR 95 % CI
No. % No. %
0–5.9 23 15 % 85 29 % 1.00 Reference 1.00 Reference
6.0–16.9 37 24 % 77 26 % 1.78 0.97, 3.25 1.75 0.90, 3.40
17.0–50.9 43 28 % 69 23 % 2.30 1.27, 4.19 2.11 1.01, 4.34
Greater or equal to 51.0 50 33 % 65 22 % 2.84 1.58, 5.13 2.04 0.92, 4.51
Only severe pneumonia cases (sensitivity analysis)
Total urinary arsenic (μg/L) Case urine samples (N = 153) Control urine samples (N = 296) Crude OR 95 % CI Adjusted OR 95 % CI
No. % No. %
0–5.9 17 13 % 85 29 % 1.00 Reference 1.00 Reference
6.0–16.9 35 26 % 77 26 % 2.73 1.18, 4.38 2.12 1.04, 4.32
17.0–50.9 38 28 % 69 23 % 2.75 1.43, 5.30 2.35 1.07, 5.17
Greater or equal to 51.0 45 33 % 65 22 % 3.46 1.82, 6.60 2.36 1.02, 5.42
*Odds ratio were adjusted for weight for height (z-score less than −2 SDs), breastfeeding in the prior week (exclusive, mixed, none), paternal education, age,
number of people living in the household (log transformed), and urinary creatinine
Table 3 Crude and adjusted odds ratios of case and control urine samples at the convalescent time point* (urinary creatinine in
adjusted model)
Convalescent Time point
All pneumonia cases (severe and very severe)
Total urinary arsenic (μg/L) Case convalescent urine samples (N= 153) Control urine samples (N= 296) Crude OR 95 % CI Adjusted OR 95 % CI
No. % No. %
0–5.9 30 20 % 85 29 % 1.00 Reference 1.00 Reference
6.0–14.9 44 29 % 67 23 % 1.86 1.06, 3.27 2.25 1.23, 4.11
15.0–41.9 39 25 % 72 24 % 1.53 0.87, 2,71 2.29 1.17, 4.47
Greater or equal to 42.0 40 26 % 72 24 % 1.57 0.89, 2.78 2.56 1.27, 5.15
Only severe pneumonia cases (sensitivity analysis)
Total urinary arsenic (μg/L) Case convalescent urine Samples (N= 153) Control urine samples (N= 296) Crude OR 95 % CI Adjusted OR 95 % CI
No. % No. %
0–5.9 24 18 % 85 29 % 1.00 Reference 1.00 Reference
6.0–14.9 39 29 % 67 23 % 2.06 1.13, 3.76 2.56 1.35, 4.85
15.0–41.9 38 28 % 72 24 % 1.87 1.03, 3.41 2.80 1.39, 5.63
Greater or equal to 42.0 34 25 % 72 24 % 1.67 0.91, 3.08 2.89 1.37, 6.08
*Odds ratio were adjusted for weight for height (z-score less than −2 SDs), breastfeeding in the prior week (exclusive, mixed, none), paternal education, age,
number of people living in the household (log transformed), and urinary creatinine
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Discussion
To our knowledge, this is the first study to assess the as-
sociation between childhood arsenic exposure and
pneumonia. We found a nearly two times higher odds of
pneumonia for children with creatinine adjusted urinary
arsenic concentrations higher than the first quartile
(≥6 μg/L), when the hospital admission time point case
and control urines were compared. An association be-
tween arsenic and respiratory infections in children at
the low observed urinary arsenic concentrations, to our
knowledge, has not been previously reported, and sug-
gests that even low to moderate arsenic exposure can
result in an increased risk of pneumonia in pediatric
populations. Pneumonia is the leading cause of death
globally for children under 5 years of age, causing an es-
timated 1.4 million deaths per year in this age group
[18]. Therefore identifying risk factors for pneumonia
provides an opportunity for interventions to reduce this
disease burden in susceptible populations. These study
findings provide preliminary evidence to support the
Table 4 Crude and adjusted odds ratios of case and control urine samples at the hospital admission timepoint (without urinary
creatinine adjustment)*
Hospital Admission Time point
All pneumonia cases (severe and very severe)
Total urinary arsenic (μg/L) Case urine samples (N = 153) Control urine samples (N = 296) Crude OR 95 % CI Adjusted OR 95 % CI
No. % No. %
0–5.9 23 15 % 85 29 % 1.00 Reference 1.00 Reference
6.0–16.9 37 24 % 77 26 % 1.78 0.97, 3.25 2.38 1.25, 4.53
17.0–50.9 43 28 % 69 23 % 2.30 1.27, 4.19 3.77 1.88, 7.56
Greater or equal to 51.0 50 33 % 65 22 % 2.84 1.58, 5.13 4.72 2.30, 9.67
Only severe pneumonia cases (sensitivity analysis)
Total urinary arsenic (μg/L) Case urine samples (N = 153) Control urine samples (N = 296) Crude OR 95 % CI Adjusted OR 95 % CI
No. % No. %
0–5.9 17 13 % 85 29 % 1.00 Reference 1.00 Reference
6.0–16.9 35 26 % 77 26 % 2.27 1.18, 4.38 2.87 1.44, 5.72
17.0–50.9 38 28 % 69 23 % 2.75 1.43, 5.30 4.10 1.95, 8.63
Greater or equal to 51.0 45 33 % 65 22 % 3.46 1.82, 6.60 5.28 2.47, 11.26
*Odds ratio were adjusted for weight for height (z-score less than −2 SDs and z-score greater or equal to −2 SDs), breastfeeding in the prior week (exclusive,
mixed, none), paternal education, age, and number of people living in the household (log transformed)
Table 5 Crude and adjusted odds ratios of case and control urine samples at the convalescent timepoint (without urinary creatinine
adjustment)*
Convalescent Time point
All pneumonia cases (severe and very severe)
Total urinary arsenic (μg/L) Case convalescent urine samples (N= 153) Control urine samples (N= 296) Crude OR 95 % CI Adjusted OR 95 % CI
No. % No. %
0–5.9 30 20 % 85 29 % 1.00 Reference 1.00 Reference
6.0–14.9 44 29 % 67 23 % 1.86 1.06, 3.27 2.10 1.16, 3.81
15.0–41.9 39 25 % 72 24 % 1.53 0.87, 2.71 1.97 1.03, 3.79
Greater or equal to 42.0 40 26 % 72 24 % 1.57 0.89, 2.78 2.03 1.04, 3.97
Only severe pneumonia cases (sensitivity analysis)
Total urinary arsenic (μg/L) Case convalescent urine samples (N= 135) Control urine samples (N= 296) Crude OR 95 % CI Adjusted OR 95 % CI
No. % No. %
0–5.9 24 18 % 85 29 % 1.00 Reference 1.00 Reference
6.0–14.9 39 29 % 67 23 % 2.06 1.13, 3.76 2.30 1.22, 4.32
15.0–41.9 38 28 % 72 24 % 1.87 1.03, 3.41 2.26 1.15, 4.46
Greater or equal to 42.0 34 25 % 72 24 % 1.67 0.91, 3.08 2.09 1.03, 4.23
*Odds ratio were adjusted for weight for height (z-score less than −2 SDs and z-score greater or equal to −2 SDs), breastfeeding in the prior week (exclusive,
mixed, none), paternal education, age, and number of people living in the household (log transformed)
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hypothesis that arsenic exposure may be a potential risk
factor for pneumonia in children under 5 years of age.
The design of this study overcomes many of the limita-
tions of previous studies trying to assess the relationship
between arsenic and respiratory health. Most previous
studies have been ecologic, use self-reported or caregiver
reported illness, and involve participants with comorbidities
[14, 17, 19–21]. In the present study, the WHO clas-
sification of severe and very severe pneumonia was
used by study physicians for diagnosis, providing a stan-
dardized case definition of illness. In addition, through the
use of urinary arsenic as a biomarker we were able to
measure both water and dietary contributions to pediatric
arsenic exposure. This is in contrast to previous evaluations
which rely on a household’s primary drinking water source
or the mother’s urinary arsenic concentration as a proxy
measure of childhood arsenic exposure [17, 20, 22, 48].
Furthermore, the nearly 2 year duration of the study
allowed us to account for seasonal variations in pneumonia
incidence, and the inclusion of the convalescent time point
provided further validation of our findings at the hospital
admission time point.
In our sensitivity analysis removing very severe pneu-
monia cases from the regression models increased the
strength of the association between arsenic and pneumo-
nia in all models. A significant association was found
between urinary arsenic and severe pneumonia at both the
hospital admission and convalescent time points for all
quartiles compared. These findings suggest that there may
be a stronger association between severe pneumonia and
urinary arsenic than for very severe pneumonia. Future
studies should use a larger sample size to investigate the
association between arsenic exposure and very severe pneu-
monia in pediatric populations.
There was only a significant OR found between the first
and the third quartile when creatinine-adjusted urinary ar-
senic concentrations and pneumonia were compared at
the hospital admission time point, in contrast to signifi-
cance for all quartiles at the convalescent time point. We
suspect this is due to case children drinking less water
than normal during their illness or water losses due to
fever, elevated respiratory rate, and vomiting associated
with their illness. Consistent with this explanation, there
were significantly elevated urinary creatinine concentra-
tions, a marker of dehydration, in case children during the
hospital admission compared to the convalescent time
point [49]. In addition, cases took significantly longer than
controls to produce a hospital admission time point urine
sample. We suspect the high ORs found in Table 4 when
urinary arsenic concentrations at the hospital time point
unadjusted for creatinine are compared is also attributed
to case children being dehydrated, and therefore having
more concentrated urine samples with higher arsenic con-
centrations. This large effect size was substantially reduced
in Table 2 when an adjustment for creatinine was used, a
measure of hydration status. Therefore the dehydration
status of study children is a potential confounder of the
association between arsenic and pneumonia at the hos-
pital admission time point, and the convalescent time
point urine sample is likely a better reflection of the case
child’s urinary arsenic concentration after they recovered
from their illness.
Beyond respiratory infections, there is also a growing body
of literature demonstrating that early life arsenic exposure is
associated with a wide variety of adverse health outcomes
later in life. A recent cross-sectional study in Chile reported
that early life arsenic exposure was associated with reduced
forced expiratory volume measured in one second and lower
forced vital capacity nearly 40 years after the high exposure
ended [4]. Consistent with this, ecological studies in Chile
have found significant associations between early life arsenic
exposure and increased risk of lung cancer [50], kidney can-
cer mortality [51], and childhood liver cancer mortality [52].
Furthermore, there is a growing body of literature demon-
strating an association between early life arsenic exposure
and decreased cognitive and motor function in children
[53–62]. These studies emphasize the need for effective ar-
senic mitigation strategies to reduce early life arsenic expo-
sures. There have been several attempts to lower arsenic
exposure in Matlab, Bangladesh through screening of ar-
senic in wells, the distribution of pond sand filters, and the
installation of arsenic removal plants [63–65]. However,
many individuals in Matlab remain arsenic exposed [64, 66].
Previous intervention studies have found that screening of
wells for arsenic when combined with arsenic education can
lower arsenic exposure, as evidenced by significant reduc-
tions in urinary arsenic concentrations [67, 68]. Therefore
this could be a potential intervention approach to imple-
ment in Matlab, to reduce arsenic exposure in susceptible
pediatric populations.
This study has several limitations. First, we lacked
prospective data on the arsenic exposure history of study
children and information on the child’s residential history.
Instead, we relied on urinary arsenic at selected time
points as a proxy of their lifetime exposure history. There-
fore we may have misclassified the exposure histories of
some study children. However, potential misclassification
of exposure is unlikely to be differential by disease status
in the case convalescent and control urine samples.
The literature suggests that spot urine is a good proxy
measurement of arsenic exposure if the source of drinking
water remains constant [40–43]. Future studies should be
conducted using prospective cohort studies in arsenic
affected areas to investigate the causality of our observed
association between pneumonia and urinary arsenic at low
concentrations. In addition these studies should collect a
residential history for each study child to determine the
amount of time they have spent using water sources and
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the arsenic concentrations of these water sources should
be measured. Second, we focused on severe and very
severe pneumonia cases and therefore cannot draw conclu-
sions on the association between arsenic and less severe
pneumonia. Third, this is a facility based study and
therefore the cases included may not be representative
of pneumonia cases that do not report to the health facil-
ity, which comprise a large fraction of the pneumonia
cases globally [69]. To assess the association between ar-
senic and pneumonia more fully would optimally require
community-based studies. Finally, we do not have arsenic
data from the primary drinking water source used by
study children therefore we cannot associate water arsenic
concentrations with pneumonia events.
Conclusions
We observed a nearly two times higher odds of pneumonia
for children with creatinine adjusted urinary arsenic concen-
trations greater than the first quartile (≥6 μg/L). This novel
finding suggests that low to moderate arsenic exposure may
be a risk factor for pneumonia in children under 5 years of
age. Many other countries around the world are also
affected by elevated levels of arsenic in groundwater sources
such as India, Nepal, Vietnam, Cambodia, Mongolia,
Taiwan, China, Chile, Argentina, Peru, Bolivia, Mexico, and
the United States. Therefore the findings from this study
have implications that are relevant globally and would bene-
fit from future confirmatory evaluations.
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